"The Immune Conundrum": Acquired Hemophilia A, Immune Thrombocytopenia, and Neutropenia in a Patient with Pancreatic Cancer.

Praveen Ramakrishnan Geethakumari, Ashwin Sama, Jaime G Caro, Charles J Yeo, Srikanth Nagalla
{"title":"\"The Immune Conundrum\": Acquired Hemophilia A, Immune Thrombocytopenia, and Neutropenia in a Patient with Pancreatic Cancer.","authors":"Praveen Ramakrishnan Geethakumari,&nbsp;Ashwin Sama,&nbsp;Jaime G Caro,&nbsp;Charles J Yeo,&nbsp;Srikanth Nagalla","doi":"10.1089/crpc.2015.29011.prg","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Malignancy-associated bleeding can pose diagnostic dilemmas. We report a unique case of paraneoplastic acquired hemophilia A (AHA), immune thrombocytopenia (ITP), and immune neutropenia in a patient with pancreatic adenocarcinoma. <b>Case Presentation:</b> A 66-year-old male with newly diagnosed pancreatic cancer and normal preoperative hematological evaluation was taken to the operating room for pancreaticoduodenectomy. The operation was aborted due to empyema of the gall bladder, cholangitis, and local extent of disease. Postoperatively, the patient developed bleeding diatheses with mucocutaneous and intra-abdominal bleeding and a prolonged activated partial thromboplastin time. Evaluation revealed high-titer factor VIII inhibitor confirming AHA. Management with bypassing agents such as recombinant activated factor VII, factor VIII inhibitor bypassing activity, and immunosuppression with steroids, cyclophosphamide, and rituximab achieved remission in 2 months. ITP developed after achieving normal factor VIII levels, which was managed with intravenous immunoglobulin. Neutropenia was detected before initiation of chemotherapy and was managed with granulocyte-colony stimulating factor. <b>Conclusion:</b> These unique challenges posed by paraneoplastic hematological syndromes warrant the need for astute clinical judgment and multidisciplinary collaboration for effective management.</p>","PeriodicalId":92486,"journal":{"name":"Case reports in pancreatic cancer","volume":"2 1","pages":"14-18"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/crpc.2015.29011.prg","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case reports in pancreatic cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/crpc.2015.29011.prg","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Background: Malignancy-associated bleeding can pose diagnostic dilemmas. We report a unique case of paraneoplastic acquired hemophilia A (AHA), immune thrombocytopenia (ITP), and immune neutropenia in a patient with pancreatic adenocarcinoma. Case Presentation: A 66-year-old male with newly diagnosed pancreatic cancer and normal preoperative hematological evaluation was taken to the operating room for pancreaticoduodenectomy. The operation was aborted due to empyema of the gall bladder, cholangitis, and local extent of disease. Postoperatively, the patient developed bleeding diatheses with mucocutaneous and intra-abdominal bleeding and a prolonged activated partial thromboplastin time. Evaluation revealed high-titer factor VIII inhibitor confirming AHA. Management with bypassing agents such as recombinant activated factor VII, factor VIII inhibitor bypassing activity, and immunosuppression with steroids, cyclophosphamide, and rituximab achieved remission in 2 months. ITP developed after achieving normal factor VIII levels, which was managed with intravenous immunoglobulin. Neutropenia was detected before initiation of chemotherapy and was managed with granulocyte-colony stimulating factor. Conclusion: These unique challenges posed by paraneoplastic hematological syndromes warrant the need for astute clinical judgment and multidisciplinary collaboration for effective management.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
“免疫难题”:获得性血友病A、免疫性血小板减少症和中性粒细胞减少症在胰腺癌患者。
背景:恶性肿瘤相关出血可造成诊断困境。我们报告一个独特的病例副肿瘤性获得性血友病a (AHA),免疫性血小板减少症(ITP),和免疫中性粒细胞减少症的胰腺腺癌患者。病例介绍:66岁男性,新诊断为胰腺癌,术前血液学检查正常,被送往手术室行胰十二指肠切除术。手术因胆囊脓肿、胆管炎及局部病变而流产。术后,患者出现出血性糖尿病伴皮肤粘膜和腹腔内出血,激活部分凝血活酶时间延长。评估显示高滴度因子VIII抑制剂证实AHA。使用重组活化因子7、因子8抑制剂等旁路药物,以及类固醇、环磷酰胺和利妥昔单抗的免疫抑制治疗,在2个月内获得缓解。ITP在达到正常因子VIII水平后发生,静脉注射免疫球蛋白进行治疗。化疗开始前检测到中性粒细胞减少,并使用粒细胞集落刺激因子进行治疗。结论:这些独特的挑战所提出的副肿瘤血液学综合征需要敏锐的临床判断和多学科合作的有效管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Nasopharyngeal Relapse of Conjunctival Melanoma Four (04) Years after Complete Resection: About One (01) Case Intraductal Papillary Mucinous Neoplasm of the Pancreas Arising in the Setting of an Intermixed Acinar Cell Cystadenoma of the Pancreas: Report of a Rare Case. Pancreatic Paraganglioma: A Case Report. Call for Papers: Case Reports in Pancreatic Cancer Late Pancreatic Fistula After Pancreaticoduodenectomy: A Case Report and Review of the Literature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1